Shandong Luye Pharmaceutical Co., Ltd.

Nanjing Luye Pharmaceutical Co., Ltd.

Other

Geneora Pharma (shijiazhuang) Co., Ltd.

Shangong Luye Pharmaceutical Co., Ltd.

Luye Innomind Pharma Shijiazhuang Co., Ltd.

Li, Youxin

Geneora Pharma Co., Ltd.

Wanhui Liu

Youxin Li

Kaoxiang Sun

Wenyan Wang

Rongcai Liang

Qilin Wang

Lifang Sun

Xuemei Zhang

Yang Lv

Mina Yang

Guanhua Du

Ying Meng

Chunjie Sha

Qingguo Meng

Fengmei Zhou

Ju Li

Fengjuan Zhao

Changbing Tu

Jun Li

Tao Wang

Kajia Su

Oilin Wang

Shixu Li

Qingchun Zhang

Shuyan Liu

Wei Sun

Fabing Zhu

Guangyi Leng

Aiping Wang

Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.

Dosage regimen of paliperidone palmitate extended-release injectable suspension

A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Risperidone sustained release microsphere composition

A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly (lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%.

Pharmaceutical compositions of goserelin sustained release microspheres

A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

The disclosure relates to a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.

Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative

The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.

Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same

Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methyl-benzoate hydrochloride, methods for preparing the same and use of the same

The present invention relates to a pharmaceutical composition with low toxicity for anti-inflammatory and anti-exudative which contains as active ingredients escin with general formula I and escin with general formula II as well as pharmaceutically acceptable carrier or excipient. In comparison with ESCIN, this pharmaceutical composition possesses the same anti-inflammatory and anti-exudative activity, but both toxicity and irritation lower remarkably.

Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation

Growing community of inventors

Yantai, China

Wanhui Liu